CSPC Pharmaceutical Collaborates with Radiance Biopharma to Develop and Commercialize RB-164 (SYS6005) as an Anti-Cancer Therapy
Shots:
- CSPC has granted Radiance exclusive rights to develop & market RB-164 in the US, Canada, EU, UK, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, & Australia, while retaining rights to other markets
- As per the deal, CSPC will get $15M upfront, ~$150M in development & regulatory milestones and ~$1B in commercial milestones, plus net sales-based tiered royalties. Both companies will jointly file an IND with the US FDA, while Radiance will lead clinical development in its licensed regions
- RB-164 is being assessed in P-I dose-escalation trial for advanced liquid & solid tumors by CSPC in China, following IND clearance by the NMPA
Ref: Globenewswire | Image: CSPC & Radiance
Related News:- BeiGene and CSPC Pharmaceutical Collaborate to Develop SYH2039 for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
